Galmed Pharmaceuticals Ltd.
GLMD evidence brief
What we can confirm
- Market Cap:
- $4.9M
What it means
What to watch
Prepared research question
What matters most for GLMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLMD
Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company developing Aramchol, an SCD1 inhibitor, for liver, cardiometabolic, and GI oncology indications, with recent pipeline expansion into CNS and prostate cancer.
Key risk: NASH trial missed endpoint
Market Cap
$4.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 7 clinical trials for Galmed Pharmaceuticals Ltd..
Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company developing Aramchol, an SCD1 inhibitor, for liver, cardiometabolic, and GI oncology indications, with recent pipeline expansion into CNS and prostate cancer.
- Galmed reported cash & equivalents of $2.9M, net income of -$2.7M, and shareholders' equity of $12.7M as of 2026-06-30 [sec].
- Lead candidate Aramchol, an SCD1 inhibitor, is the most clinically advanced in its class [news · 2025-05-27].
- A Phase 2b trial of Aramchol in NASH showed a placebo-corrected decrease in liver triglycerides but did not meet prespecified significance (P = 0.066) [catalyst].
- Galmed announced a brain-penetrating formulation of Aramchol for potential CNS applications, including Parkinson's disease [news · 2026-04-09].
- A proprietary pharmacodynamic biomarker signature for Aramchol was identified, potentially expanding its use beyond NASH [news · 2025-05-27].
What works
- Aramchol is the most clinically advanced SCD1 inhibitor, with a proprietary biomarker signature that may enable targeted development across multiple indications [news · 2025-05-27].
- The company has expanded its pipeline into CNS (brain-penetrating formulation) and oncology (prostate cancer combination study), diversifying risk beyond NASH [news · 2026-04-09] [news · 2026-08-17].
- Galmed has active partnerships, including a research collaboration with Ramot at Tel Aviv University for metastatic brain cancer [news · 2026-04-14].
What to weigh
- The Phase 2b NASH trial of Aramchol did not meet its prespecified significance endpoint (P = 0.066), raising uncertainty about its efficacy in that indication [catalyst].
- Cash position is limited at $2.9M as of 2026-06-30, which may constrain operations without additional financing [sec].
- The company reported a net loss of $2.7M for the period ending 2026-06-30, indicating ongoing cash burn [sec].
- Much of the pipeline is at early preclinical or Phase 1 stage, with no approved products generating revenue [news · 2026-04-09] [news · 2026-08-17].
From the filings
Quoted directly from source documents.
Aramchol Phase 2b NASH trial did not meet significance
“Aramchol 600 mg produced a placebo-corrected decrease in liver triglycerides without meeting the prespecified significance (-3.1, 95% confidence interval (CI) -6.4 to 0.2, P = 0.066)”
Catalysts · October 31, 2021
Proprietary biomarker signature for Aramchol identified
“the discovery of a proprietary pharmacodynamic (PD) blood-based biomarker signature for its lead candidate, Aramchol”
News · May 27, 2025
Catalyst timeline
- 2021-10-31 · Trial_Readout: Aramchol Phase 2b NASH trial — Aramchol 600 mg did not meet prespecified significance in reducing liver triglycerides (P=0.066).
- 2025-02-15 · Phase1_Start: Aramchol Meglumine bioavailability study — Phase 1 study comparing pharmacokinetics of Aramchol Meglumine granules to tablets in healthy volunteers.
- 2025-06-01 · Phase2_Start: Aramchol Meglumine proof-of-concept study — A randomized, placebo-controlled, double-blind study to evaluate safety, tolerability, and efficacy of Aramchol Meglumine.
Risks & what to watch (4)›
Key risks
- NASH trial missed endpoint — Phase 2b trial of Aramchol in NASH did not meet prespecified significance (P=0.066) [catalyst].
- Limited cash runway — Cash & equivalents of $2.9M as of 2026-06-30 may be insufficient for late-stage trials [sec].
- No approved products — All programs are preclinical or Phase 1/2; no revenue-generating products [news].
- Early-stage pipeline uncertainty — CNS and oncology programs are at preclinical or Phase 1 stage, with no efficacy data yet [news].
What to watch
- Results from the ongoing Phase 2 study of Aramchol Meglumine (started 2025-06-01) [catalyst].
- Outcome of the preclinical combination study of Aramchol with enzalutamide for prostate cancer [news · 2026-08-17].
- Progress of the brain-penetrating Aramchol formulation toward clinical trials [news · 2026-04-09].
- Financial updates and potential financing events given limited cash position [sec].
Sources: Catalysts · Competitor trials · News · Generated October 3, 2026 · How we verify sources →
Run Galmed Pharmaceuticals Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Galmed Pharmaceuticals Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$71K
| Holder | Shares | Value |
|---|---|---|
| two sigma investments, lp | 80,177 | $39K |
| xtx topco ltd | 22,396 | $11K |
| jane street group, llc | 16,445 | $8K |
| two sigma securities, llc | 11,971 | $6K |
| citadel advisors llc | 11,382 | $6K |
| ubs group ag | 2,546 | $1K |
| bnp paribas financial markets | 600 | $294 |
| morgan stanley | 157 | $77 |
| wells fargo & company/mn | 43 | $21 |
| sbi securities co., ltd. | 16 | $8 |
Showing top 10 of 16 institutional holders of Galmed Pharmaceuticals Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 7.8%
- Days to cover
- 0.1
- Shares short
- 502,390
- Daily short volume (Aug 14, 2026)
- 21.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GLMD short interestFrequently asked questions
What is the AI investment thesis for Galmed Pharmaceuticals Ltd.?
Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company developing Aramchol, an SCD1 inhibitor, for liver, cardiometabolic, and GI oncology indications, with recent pipeline expansion into CNS and prostate cancer.
Who is the CEO of Galmed Pharmaceuticals Ltd.?
Mr. Allen Baharaff is the chief executive officer of Galmed Pharmaceuticals Ltd. (GLMD).
Where is Galmed Pharmaceuticals Ltd. headquartered?
Galmed Pharmaceuticals Ltd. (GLMD) is headquartered in Ramat Gan, Israel.
What therapeutic areas does Galmed Pharmaceuticals Ltd. focus on?
Galmed Pharmaceuticals Ltd. develops therapies across Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.